# Molecular Signatures in Inflammatory Skin Disease

> **NCT03358693** · — · RECRUITING · sponsor: **Prof. Dr. Stephan Weidinger** · enrollment: 300 (estimated)

## Conditions studied

- Atopic Dermatitis
- Psoriasis

## Interventions

- **DRUG:** Anti-TNF
- **DRUG:** Anti-IL12/23
- **DRUG:** Anti-IL17
- **DRUG:** Dupilumab
- **DRUG:** Anti-IL23
- **DRUG:** Baricitinib
- **DRUG:** Abrocitinib
- **DRUG:** Upadacitinib
- **DRUG:** Tralokinumab
- **DRUG:** Lebrikizumab
- **DRUG:** Nemolizumab

## Key facts

- **NCT ID:** NCT03358693
- **Lead sponsor:** Prof. Dr. Stephan Weidinger
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2017-01-20
- **Primary completion:** 2028-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2025-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03358693

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03358693, "Molecular Signatures in Inflammatory Skin Disease". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03358693. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*